Watchlist Price Alert

Apogee Therapeutics Inc. (APGE)

NASDAQ: APGE · Real-Time Price · USD

42.68

-1.80 (-4.05%)

At close: Jun 16, 2025, 3:59 PM

42.50

-0.42%

After-hours: Jun 16, 2025, 06:29 PM EDT

-4.05% (1D)

Bid	41.5
Market Cap	2.54B
Revenue (ttm)	n/a
Net Income (ttm)	-150.05M
EPS (ttm)	-3.61
PE Ratio (ttm)	-11.82
Forward PE	-7.6
Analyst	Buy

Ask	43.08
Volume	847,563
Avg. Volume (20D)	712,488
Open	44.65
Previous Close	44.48
Day's Range	42.63 - 44.65
52-Week Range	26.20 - 63.50
Beta	1.39

About APGE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol APGE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for APGE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+6.14%

Apogee Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

7 months ago

-5.14%

Apogee Therapeutics shares are trading lower. The company reported Q3 financial results.

News

1 week ago · zacks.com

Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questi...

3 weeks ago · zacks.com

Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet

The consensus price target hints at a 132.7% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

1 month ago · seekingalpha.com

Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class

Apogee Therapeutics, Inc. achieved positive interim results from phase 1b study using APG808 for the treatment of patients with Asthma. Interim 16-week data from the phase 2 APEX study using APG777 fo...

1 month ago · zacks.com

Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade

The mean of analysts' price targets for Apogee Therapeutics Inc. (APGE) points to a 134% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

2 months ago · seekingalpha.com

Apogee Therapeutics: Engineering Biologic Dominance

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious pipeline development in inflammatory diseases. Significant R&D investments i...